A Redox-Triggered Autophagy-Induced Nanoplatform with PD-L1 Inhibition for Enhancing Combined Chemo-Immunotherapy
ACS Nano · 21.05.2024 · 18 (20) · 12870-12884
DOI: 10.1021/acsnano.4c00227 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Nano, online erschienen am 10.05.2024. Verfasst von Ming Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: National Engineering Research Center for Biomaterials, Sichuan University, Chengdu 610064, China. Hauptthemen laut MEDLINE: Autophagy, B7-H1 Antigen, Immunotherapy, Nanoparticles. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Science and Technology Support Plan for Youth Innovation of Colleges and Universities of Shandong Province of China, Natural Science Foundation of Shandong Province.
Abstract (Originalsprache)
Epirubicin (EPI) alone can trigger mildly protective autophagy in residual tumor cells, resulting in an immunosuppressive microenvironment. This accelerates the recurrence of residual tumors and leads to antiprogrammed death ligand 1 (anti-PD-1)/PD-L1 therapy resistance, posing a significant clinical challenge in tumor immunotherapy. The combination of checkpoint inhibitors targeting the PD-1/PD-L1 pathway and amplifying autophagy presents an innovative approach to tumor treatment, which can prevent tumor immune escape and enhance therapeutic recognition. Herein, we aimed to synthesize a redox-triggered autophagy-induced nanoplatform with SA&EA-induced PD-L1 inhibition. The hyaluronic acid (HA) skeleton and arginine segment promoted active nanoplatform targeting, cell uptake, and penetration. The PLGLAG peptide was cleaved by overexpressing matrix metalloproteinase-2 (MMP-2) in the tumor microenvironment, and the PD-L1 inhibitor D-PPA was released to inhibit tumor immune escape. The intense autophagy inducers, STF-62247 and EPI, were released owing to the cleavage of disulfide bonds influenced by the high glutathione (GSH) concentration in tumor cells. The combination of EPI and STF induced apoptosis and autophagic cell death, effectively eliminating a majority of tumor cells. This indicated that the SA&EA nanoplatform has better therapeutic efficacy than the single STF@AHMPP and EPI@AHMPTP groups. This research provided a way to set up a redox-triggered autophagy-induced nanoplatform with PD-L1 inhibition to enhance chemo-immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Engineering Research Center for Biomaterials, Sichuan University, Chengdu 610064, China.
- College of Biomedical Engineering, Sichuan University, 29 Wangjiang Road, Chengdu, Sichuan 610064, China.
- Sichuan Kelun Pharmaceutical Research Institute Co. Ltd., Chengdu 611130, China.
- Department of Pharmaceutics, School of Pharmacy, Qingdao University, Qingdao 266073, China.
- Department of Clinical Laboratory, No.971 Hospital of the People's Liberation Army Navy, Qingdao 266021, China.
ORCID-Profile: Yujiang Fan, Yan Liang
Förderung
- Science and Technology Support Plan for Youth Innovation of Colleges and Universities of Shandong Province of China
- Natural Science Foundation of Shandong Province
Zitieren
APA
Li, M., Zhao, D., Yan, J., Fu, X., Li, F., Liu, G., Fan, Y., Liang, Y., & Zhang, X. (2024). A Redox-Triggered Autophagy-Induced Nanoplatform with PD-L1 Inhibition for Enhancing Combined Chemo-Immunotherapy. ACS Nano, 18(20), 12870-12884. https://doi.org/10.1021/acsnano.4c00227
Vancouver
Li M, Zhao D, Yan J, Fu X, Li F, Liu G, et al. A Redox-Triggered Autophagy-Induced Nanoplatform with PD-L1 Inhibition for Enhancing Combined Chemo-Immunotherapy. ACS Nano. 2024;18(20):12870-12884. doi:10.1021/acsnano.4c00227
BibTeX
@article{Li2024,
author = {Li, Ming and Zhao, Dong and Yan, Jianqin and Fu, Xiaoheng and Li, Fashun and Liu, Gecen and Fan, Yujiang and Liang, Yan and Zhang, Xingdong},
title = {A Redox-Triggered Autophagy-Induced Nanoplatform with PD-L1 Inhibition for Enhancing Combined Chemo-Immunotherapy},
journal = {ACS Nano},
year = {2024},
volume = {18},
number = {20},
pages = {12870--12884},
doi = {10.1021/acsnano.4c00227}
}
EUVIMED